Zacks Research initiated coverage on shares of Lycia Therapeutics (NASDAQ:LYCA – Free Report) in a research report report published on Thursday,Zacks reports. The brokerage issued a hold rating on the stock.
LYCA has been the topic of a number of other research reports. Evercore assumed coverage on Lycia Therapeutics in a research report on Tuesday, November 17th. They set an “outperform” rating and a $43.00 price objective on the stock. Jefferies Financial Group began coverage on Lycia Therapeutics in a report on Tuesday. They issued a “buy” rating and a $50.00 target price for the company. Guggenheim started coverage on Lycia Therapeutics in a research note on Tuesday, November 17th. They set a “buy” rating and a $75.00 target price for the company. TD Cowen began coverage on Lycia Therapeutics in a research note on Tuesday, November 17th. They set a “buy” rating for the company. Finally, Wall Street Zen upgraded Lycia Therapeutics to a “hold” rating in a report on Saturday, October 31st. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $54.00.
View Our Latest Research Report on LYCA
Lycia Therapeutics Stock Up 4.1%
Insider Activity
In other news, major shareholder Venrock Healthcare Capital Par bought 8,305 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was purchased at an average price of $26.95 per share, for a total transaction of $223,819.75. Following the completion of the purchase, the insider owned 6,858,542 shares in the company, valued at approximately $184,837,706.90. This trade represents a 0.12% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders have acquired 2,078,749 shares of company stock worth $38,526,342.
About Lycia Therapeutics
Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies. The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.
Featured Articles
- Five stocks we like better than Lycia Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Lycia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
